Liamocin Antibacterial Oils for Dairy Cow Infection Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for preventing or treating infections caused by Streptococcus spp. in dairy cows during the dry period are inadequate, leading to economic losses and the risk of antibiotic resistance, as systemic antibiotics can contaminate milk and promote resistant microorganisms.
Innovation Solution
Development of novel compounds, specifically liamocins, produced by Aureobasidium pullulans, which have antibacterial activity against Streptococcus spp. and other bacteria, allowing for topical, oral, or parenteral administration to prevent or treat bacterial infections, and can be used as a disinfectant to kill bacteria on surfaces.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If systemic antibiotics are used to prevent or treat Streptococcus infections in dairy cows during the dry period, then bacterial infections are effectively controlled, but antibiotic residues contaminate milk and promote resistant microorganisms
Solution Approach 1:
The patent segments the treatment approach by using different agents for different purposes: liamocins are applied topically to the teat and udder for localized prevention, while systemic antibiotics are reserved for treating established infections. This segmentation eliminates antibiotic contamination in milk during the dry period while maintaining effective infection control through the combination of topical liamocin application and targeted systemic treatment when needed.
Solution Approach 2:
Liamocins serve as an intermediary substance that provides antibacterial protection during the dry period without the harmful effects of systemic antibiotics. The liamocin-containing composition is applied topically as a mediator between the need for infection prevention and the avoidance of antibiotic contamination, allowing effective local protection while preventing the development of resistant microorganisms and milk contamination.
2Reliability
If topical disinfectants are applied to prevent bacterial infections, then bacterial growth is inhibited, but the disinfectant must be effective against resistant bacteria strains
Solution Approach 1:
The patent utilizes parameter changes by employing liamocins with specific molecular structures (varying chain lengths and head groups) that provide broad-spectrum activity against different bacterial strains including resistant ones. The liamocin composition can be adjusted in terms of concentration, specific liamocin variants, and formulation parameters to maintain effectiveness against evolving resistant strains while remaining safe for dairy cow application.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Liamocins effectively reduce bacterial viability and prevent bacterial growth, offering a safer alternative to systemic antibiotics by targeting specific bacteria without contaminating milk, thereby reducing economic losses and antibiotic resistance risks.
Implementation Method 1
The liamocin-containing oil and the individual liamocins possess anti-bacterial activity
Data Source
AI summary
Compounds, called liamocins from Aureobasidium pullulans, having the general structure in Formula 1 are disclosed.where R1 is either COCH3 or H; and R2 is between two to ten O-linked 3,5-dihydroxydecanoate; and R3 can be a polyol (e.g., L- or D-glycerol, L- or D-threitol, L- or D-erythritol, L- or D-arabitol, L- or D-xylitol, L- or D-lyxitol, L- or D-ribitol, L- or D-allitol, L- or D-altritol, L- or D-mannitol, L- or D-iditol, L- or D-gulitol, L- or D-glucitol (also called sorbitol), L- or D-galactitol (also called dulcitol), and L- or D-talitol), 2-amino-D-mannitol, 2N-acetylamino-D-mannitol, L-rhamnitol, or D-fucitol; except when R3 is D-mannitol, R2 is not 2 nor 3 O-linked 3,5-dihydroxydecanoate chains. These liamocins described above in addition to D-mannitol liamocin A1, D-mannitol liamocin A2, D-mannitol liamocin B1, and D-mannitol liamocin B2, alone or in combination with each other, can be used to kill certain bacteria and to treat certain bacterial infections.